Free Trial
OTCMKTS:IPSEY

IPSEN (IPSEY) Stock Price, News & Analysis

IPSEN logo
$29.34 -0.77 (-2.54%)
As of 06/18/2025 03:32 PM Eastern

About IPSEN Stock (OTCMKTS:IPSEY)

Key Stats

Today's Range
$29.34
$29.76
50-Day Range
$25.77
$30.95
52-Week Range
$25.11
$32.25
Volume
726 shs
Average Volume
1,301 shs
Market Capitalization
$9.84 billion
P/E Ratio
N/A
Dividend Yield
0.89%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEN and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Stock News Headlines

An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
See More Headlines

IPSEY Stock Analysis - Frequently Asked Questions

IPSEN's stock was trading at $28.97 on January 1st, 2025. Since then, IPSEY stock has increased by 1.3% and is now trading at $29.34.
View the best growth stocks for 2025 here
.

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Ex-Dividend for 6/25 Dividend
6/09/2025
Record date for 6/25 Dividend
6/10/2025
Today
6/19/2025
Dividend Payable
6/25/2025
Next Earnings (Estimated)
7/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPSEY
CIK
N/A
Employees
5,325
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.87 billion
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$9.84 billion
Optionable
Not Optionable
Beta
0.54

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (OTCMKTS:IPSEY) was last updated on 6/19/2025 by MarketBeat.com Staff
From Our Partners